Pharmacokinetic and safety study of subcutaneously administered weekly ING-1, a human engineered™ monoclonal antibody targeting human EpCAM, in patients with advanced solid tumors

S. Goel, R. J. Bauer, K. Desai, A. Bulgaru, T. Iqbal, B. K. Strachan, G. Kim, A. Kaubisch, G. F. Vanhove, G. Goldberg, S. Mani

Research output: Contribution to journal › Article › peer-review

23 Scopus citations

Fingerprint

Dive into the research topics of 'Pharmacokinetic and safety study of subcutaneously administered weekly ING-1, a human engineered™ monoclonal antibody targeting human EpCAM, in patients with advanced solid tumors'. Together they form a unique fingerprint.

Medicine & Life Sciences